Amplify ETF Trust Amplify International Enhanced Dividend Income ETF (ARCA: IDVO)

Latest News for Amplify ETF Trust Amplify International Enhanced Dividend Income ETF (ARCA:IDVO)

Toyota Photo by RYO Alexandre on Shutterstock

Equities

News

Markets

Movers

General

DIVD

IDVO

Toyota (TM) shares decline despite unveiling a $1.4B investment in its Princeton facility for producing electric SUVs, part of its U.S. reinvestment strategy.

What&#39;s Going On With Toyota Shares After Revealing $1.4B Investment At Princeton Facility For Making Electric SUVs?

Regulations

Toyota shares are dropping in premarket trading after the company recalls 211,000 Prius cars due to door handle issues, posing safety risks.

What&#39;s Going On With Toyota Shares After Recalling 211,000 Prius Cars Owing To Door Handle Issues?

Businessman.Markets.Shutterstock

Large Cap

Specialty ETFs

New ETFs

Federal Reserve

Exclusives

Pre-Market Outlook

Trading Ideas

Interview

ETFs

BABA

NVDA

SIEGY

TCEHY

Tim Seymour says the Federal Reserve is cutting rates for a reason - stalling growth.

EXCLUSIVE: Find Value In Large Multinationals And Catch The Dividend Yield, Says Tim Seymour

Amplify ETF Trust Amplify International Enhanced Dividend Income ETF

Guidance

Velo3D Sees FY24 Revenue $80M-$95M Vs $121.290M Est.

<a href="https://about.att.com/story/2024/ast-spacemobile-commercial-agreement.html" title="https://about.att.com/story/2024/ast-spacemobile-commercial-agreement.html">https://about.att.com/story/2024/ast-spacemobile-commercial-agreement.html</a>

ASTS

AT&T and AST SpaceMobile Announce Definitive Commercial Agreement

Velo3D Sees Q2 Revenue Growth More Than 30%

TOMI Environmental Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOMZ#NASDAQ">TOMZ</a>) reported quarterly losses of $(0.07) per share. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $1.114 million which missed the analyst consensus estimate of $2.575 million by 56.74 percent. This is a 29.58 percent decrease over sales of $1.582 million the same period last year.

Earnings

Earnings Misses

TOMZ

TOMI Environmental Solns Q1 2024 GAAP EPS $(0.07) Down From $(0.06) YoY, Sales $1.114M Miss $2.575M Estimate

BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) reported quarterly losses of $(0.07) per share. This is a 250 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $3.19 million in sales this quarter. This is a 3.89 percent increase over sales of $3.07 million the same period last year.

BTBD

BT Brands Q1 EPS $(0.07) Down From $(0.02) YoY, Sales $3.19M Up From $3.07M YoY

Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) reported quarterly earnings From Continuing Operations of $0.43 per share which beat the analyst consensus estimate of $0.33 by 30.3 percent. This is a 65.38 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $39.689 million which beat the analyst consensus estimate of $38.200 million by 3.90 percent. This is a 20.75 percent increase over sales of $32.869 million the same period last year.

Earnings Beats

CWCO

Consolidated Water Co Q1 2024 GAAP EPS From Continuing Operations $0.43 Beats $0.33 Estimate, Sales $39.689M Beat $38.200M Estimate

CSCO

Cisco Sees Q4 Adj. EPS $0.84-$0.86 vs $0.85 Est., Revenue $13.4B-$13.6B vs $13.23B Est.; Sees FY24 Adj. EPS $3.69-$3.71 vs $3.67 Est., Revenue $53.6B-$53.8B vs $53.14B Est.

WIIM

Cisco shares are trading higher after the company reported better-than-expected Q3 financial results.

NeuroMetrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) reported quarterly losses of $(1.67) per share. This is a 1.83 percent decrease over losses of $(1.64) per share from the same period last year. The company reported $1.09 million in sales this quarter. This is a 36.64 percent decrease over sales of $1.73 million the same period last year.

NURO

NeuroMetrix Q1 EPS $(1.67) Down From $(1.64) YoY, Sales $1.09M Down From $1.73M YoY

Velo3D (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $9.79 million which missed the analyst consensus estimate of $20.90 million by 53.18 percent. This is a 63.50 percent decrease over sales of $26.81 million the same period last year.

Velo3D Q1 2024 Adj EPS $(0.08) Misses $(0.05) Estimate, Sales $9.79M Miss $20.90M Estimate

Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.58) by 8.62 percent.

OMER

Omeros Q1 2024 Adj EPS $(0.63) Misses $(0.58) Estimate

Remaining Directors Narrowly Elected by Pitifully Low Percentages &nbsp;
Stockholders Deliver Clear Mandate for Change
NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Blackwells Capital, an owner of 1,000 shares of Ashford Hospitality Trust, Inc. ("Ashford" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>), announced today that directors Monty J. Bennett and Kamal Jafarnia failed to receive the requisite number of votes required for re-election to the Company's Board of Directors (the "Board") at the Company's 2024 annual meeting of stockholders (the "2024 Annual Meeting") and were forced to tender their resignations. The Company's remaining nominees were narrowly re-elected by disturbingly low numbers.
Blackwells achieved this result despite the Company's refusal to produce a stockholder list, and with just one mailing to stockholders. In an attempt to ward off Blackwells' campaign, the Company spun up a familiar playbook employed by Chairman Monty Bennett, which included an aggressive and misleading PR campaign, and the manipulation of Ashford's corporate machinery to entrench the Board, going as far as changing the meeting quorum requirement in an effort to ensure re-election of the failing incumbent Board members.

Management

Shareholder Blackwells Capital Forces Ashford Hospitality Trust's Chairman Monty J. Bennett And Director Kamal Jafarnia To Resign

Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 53.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $4.993 thousand which missed the analyst consensus estimate of $816.667 thousand by 99.39 percent.

EYEN

Eyenovia Q1 2024 GAAP EPS $(0.23) Misses $(0.17) Estimate, Sales $4.993K Miss $816.667K Estimate

Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.82 by 7.32 percent. The company reported quarterly sales of $12.700 billion which beat the analyst consensus estimate of $12.531 billion by 1.35 percent. This is a 12.84 percent decrease over sales of $14.571 billion the same period last year.

Cisco Systems Q3 2024 Adj EPS $0.88 Beats $0.82 Estimate, Sales $12.700B Beat $12.531B Estimate

Qiang He&rsquo;s resignation was due to his personal reasons and not a result of any disagreement with the Company&rsquo;s operations, policies or procedures. Lei Xia, the Chief Executive Officer of the Company, will temporarily serve the capacity of Chief Financial Officer of the Company after Mr. He&rsquo;s resignation, until the Company appoints He&rsquo;s replacement.

ICZOOM Group Says Qiang He Tendered His Resignation As CFO, Effective From May 15, 2024 - Filing

VBI Vaccines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) reported quarterly losses of $(0.73) per share. This is a 77.33 percent increase over losses of $(3.22) per share from the same period last year. The company reported $1.21 million in sales this quarter. This is a 150.31 percent increase over sales of $485.00 thousand the same period last year.

VBIV

VBI Vaccines Q1 EPS $(0.73) Up From $(3.22) YoY, Sales $1.21M Up From $485.00K YoY

Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) reported quarterly losses of $(4.77) per share which missed the analyst consensus estimate of $(2.64) by 80.68 percent. The company reported quarterly sales of $300.00 thousand which missed the analyst consensus estimate of $1.88 million by 84.00 percent. This is a 400.00 percent increase over sales of $60.00 thousand the same period last year.

YTEN

Yield10 Bioscience Q1 2024 Adj EPS $(4.77) Misses $(2.64) Estimate, Sales $300.00K Miss $1.88M Estimate

NeuroMetrix Q1 Revenue $1.093M Down From $1.724M YoY

Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $20.322 million which missed the analyst consensus estimate of $21.583 million by 5.84 percent. This is a 5.24 percent decrease over sales of $21.446 million the same period last year.

USIO

Usio Q1 2024 GAAP EPS $(0.01) Misses $0.01 Estimate, Sales $20.322M Miss $21.583M Estimate

<ul>
<li>BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers</li>
<li>Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatments</li>
<li>Important milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future commercial manufacturing of CAR-T therapies</li>
<li>Complements existing collaborations with Galapagos' other manufacturing partners</li>
</ul>
Mechelen, Belgium; 15 May 2024, 22:01 CET; Galapagos NV ((Euronext &amp;, NASDAQ:<a href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) and Blood Centers of America (BCA) today announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos' CAR-T cell therapies through BCA's network in the U.S.
Under the terms of the collaboration agreement, BCA will provide access to its extensive network of over 50 community blood centers in 43 states for Good Manufacturing Practice compliant manufacturing for Galapagos' CAR-T hemato-oncology clinical program. This agreement complements existing collaborations between Galapagos and Landmark Bio and Thermo Fisher Scientific.
Galapagos will leverage BCA's network to initiate technology transfer to multiple sites in parallel for the decentralized manufacturing of its CAR-T product candidates, close to cancer treatment centers, while also accessing apheresis capacity at BCA sites when required. In addition, BCA will play a crucial coordinating role by supporting site initiation and onboarding to accelerate Galapagos' efforts and ensure consistent quality.
Galapagos' innovative, decentralized manufacturing platform could address many of the limitations that currently available CAR-T production is facing. It has the potential to offer greater speed and scalability, with the delivery of fresh, fit cells with a vein-to-vein time of seven days and the possibility for greater physician control and improved patient experience.

Biotech

GLPG

Galapagos And Blood Centers Of America Collaborate To Expand Galapagos' Decentralized CAR-T Manufacturing Network In The U.S.

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1433

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1372

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1355

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1324

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1413

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1437

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1440

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1472

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1527

Amplify International Enhanced Dividend Income ETF declares monthly distribution of $0.1515

Amplify International Enhanced Dividend Income ETF

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Amplify ETF Trust Amplify International Enhanced Dividend Income ETF (ARCA:IDVO)

Thursday, April 25, 2024

Wednesday, April 17, 2024

Friday, December 22, 2023